CR20230069A - Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 - Google Patents
Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2Info
- Publication number
- CR20230069A CR20230069A CR20230069A CR20230069A CR20230069A CR 20230069 A CR20230069 A CR 20230069A CR 20230069 A CR20230069 A CR 20230069A CR 20230069 A CR20230069 A CR 20230069A CR 20230069 A CR20230069 A CR 20230069A
- Authority
- CR
- Costa Rica
- Prior art keywords
- trem2
- agonists
- colony
- treatment
- stimulating factor
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 title abstract 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 abstract 7
- 101710174937 Triggering receptor expressed on myeloid cells 2 Proteins 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona un método para tratar una enfermedad o trastorno causado por y/o asociado con una disfunción del CSF1R en un paciente humano, el método comprende administrar al paciente que lo necesita una cantidad eficaz de un compuesto que aumenta la actividad del receptor activador expresado en células mieloides 2 (TREM2). En algunas modalidades, el compuesto que aumenta la actividad de TREM2 es un agonista de TREM2. En algunas modalidades, el agonista de TREM2 es un agonista de molécula pequeña de TREM2 o un agonista de anticuerpo de TREM2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063061315P | 2020-08-05 | 2020-08-05 | |
US202063129852P | 2020-12-23 | 2020-12-23 | |
PCT/US2021/071115 WO2022032293A2 (en) | 2020-08-05 | 2021-08-05 | Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230069A true CR20230069A (es) | 2023-08-16 |
Family
ID=80117708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230069A CR20230069A (es) | 2020-08-05 | 2021-08-05 | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220089726A1 (es) |
EP (1) | EP4192881A4 (es) |
JP (1) | JP2023536916A (es) |
KR (1) | KR20230061386A (es) |
AU (1) | AU2021320553A1 (es) |
BR (1) | BR112023002093A2 (es) |
CA (1) | CA3190581A1 (es) |
CO (1) | CO2023002206A2 (es) |
CR (1) | CR20230069A (es) |
IL (1) | IL300327A (es) |
MX (1) | MX2023001546A (es) |
TW (1) | TW202218683A (es) |
WO (1) | WO2022032293A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220110537A (ko) | 2019-12-05 | 2022-08-08 | 알렉터 엘엘씨 | 항-trem2 항체 사용 방법 |
WO2023192288A1 (en) * | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024052343A1 (en) * | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Trem-2 agonists for the treatment of marfan syndrome |
WO2024097798A1 (en) * | 2022-11-01 | 2024-05-10 | Vigil Neuroscience, Inc. | Anti-trem2 antibody and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4066859A1 (en) * | 2014-08-08 | 2022-10-05 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
CN108738323B (zh) * | 2015-10-06 | 2023-05-26 | 艾利妥 | 抗trem2抗体及其使用方法 |
JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
UY38407A (es) * | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
JP2022513114A (ja) * | 2018-11-26 | 2022-02-07 | デナリ セラピューティクス インコーポレイテッド | 脂質代謝調節不全の治療方法 |
-
2021
- 2021-08-05 MX MX2023001546A patent/MX2023001546A/es unknown
- 2021-08-05 CA CA3190581A patent/CA3190581A1/en active Pending
- 2021-08-05 US US17/444,511 patent/US20220089726A1/en not_active Abandoned
- 2021-08-05 TW TW110128963A patent/TW202218683A/zh unknown
- 2021-08-05 EP EP21854032.6A patent/EP4192881A4/en active Pending
- 2021-08-05 BR BR112023002093A patent/BR112023002093A2/pt not_active Application Discontinuation
- 2021-08-05 IL IL300327A patent/IL300327A/en unknown
- 2021-08-05 KR KR1020237007468A patent/KR20230061386A/ko unknown
- 2021-08-05 JP JP2023507597A patent/JP2023536916A/ja active Pending
- 2021-08-05 CR CR20230069A patent/CR20230069A/es unknown
- 2021-08-05 AU AU2021320553A patent/AU2021320553A1/en active Pending
- 2021-08-05 WO PCT/US2021/071115 patent/WO2022032293A2/en active Application Filing
-
2023
- 2023-02-27 CO CONC2023/0002206A patent/CO2023002206A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3190581A1 (en) | 2022-02-10 |
KR20230061386A (ko) | 2023-05-08 |
EP4192881A4 (en) | 2024-08-14 |
US20220089726A1 (en) | 2022-03-24 |
JP2023536916A (ja) | 2023-08-30 |
AU2021320553A1 (en) | 2023-03-02 |
BR112023002093A2 (pt) | 2023-04-25 |
IL300327A (en) | 2023-04-01 |
CO2023002206A2 (es) | 2023-06-09 |
TW202218683A (zh) | 2022-05-16 |
MX2023001546A (es) | 2023-05-03 |
WO2022032293A2 (en) | 2022-02-10 |
EP4192881A2 (en) | 2023-06-14 |
WO2022032293A3 (en) | 2022-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20230069A (es) | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2 | |
Li et al. | Chronic stress exacerbates neuropathic pain via the integration of stress-affect–related information with nociceptive information in the central nucleus of the amygdala | |
KR101754045B1 (ko) | 항코넥신제로서의 플레카이니드의 용도 및 향정신 약물 효과를 증강시키는 방법 | |
RU2010108429A (ru) | Регуляторы ммр-9 и их применение | |
Przeklasa-Muszyńska et al. | Intravenous lidocaine infusions in a multidirectional model of treatment of neuropathic pain patients | |
Bonta et al. | 1-Hydroxy-3-amino-pyrrolidone-2 (HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases | |
JP2009527497A (ja) | 神経原性振戦を調節するための局所麻酔剤の新規適用 | |
JPS59130215A (ja) | 錐体外運動障害の軽減法 | |
US7723302B2 (en) | Method of treating Parkinson's disease | |
Kline IV et al. | Catechol-O-methyltransferase inhibition alters pain and anxiety-related volitional behaviors through activation of β-adrenergic receptors in the rat | |
MX2023006397A (es) | Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2. | |
Kim et al. | Biochemical and functional characterization of alpha-adrenergic receptors in the rabbit vagina | |
Costa et al. | Comparison of analgesia and ataxia degree obtained between three dosages of tramadol in cattle. | |
Millar et al. | Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice | |
Ding et al. | The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury | |
Jiang et al. | Successful reversal of opioid-induced hyperalgesia and allodynia with duloxetine | |
Ishii et al. | Circulating adrenaline released by sympathoadrenal activation elicits acute vasodilatation in the rat masseter muscle | |
MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
MX2022011527A (es) | Formulaciones de oligosacaridos de agonistas del receptor opioide kappa. | |
Lacroix et al. | The role of ATP in non‐adrenergic sympathetic vascular control of the nasal mucosa in anaesthetized cats and dogs. | |
Kim et al. | Synthetic neurotensin analogues are nontoxic analgesics for the rabbit cornea | |
Ponzoni et al. | Increased waking after intra-accumbens injection of m-chlorophenylbiguanide: prevention with serotonin or dopamine receptor antagonists | |
Gallach et al. | Sex and pain: Sexual satisfaction and sexual function in a sample of patients with chronic, non-pelvic pain | |
Jain | Psychoneuroimmunology of Fatigue and Sleep Disturbance: The Role of Pro-inflammatory Cytokines Shamini Jain, Julienne Bower, and Michael R. Irwin | |
Donnerer | Primary sensory neurones and naloxone-precipitated morphine withdrawal. |